Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors
A Phase 1 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain
Sponsor: National Cancer Institute (NCI)
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from National Cancer Institute (NCI)
Other Adult Anaplastic Astrocytoma trials with similar outcome
Listed as NCT01148966, this PHASE1 trial focuses on Adult Anaplastic Astrocytoma and Adult Anaplastic Oligodendroglioma and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
Phase: PHASE1_PHASE2 → PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Jun 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Washington
For direct contact, visit the study record on ClinicalTrials.gov .